Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...

Blood tests measure the level of PSA protein, produced by the prostate gland, and may help detect early signs of prostate ...

The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

NEW YORK – The US Food and Drug Administration on Friday expanded the indication for Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use prior to chemotherapy in ...

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...

The WOLVERINE meta-analysis reinforces the role of MDT in delaying disease progression in patients with oligometastatic ...